TCR-fo­cused Im­mat­ics adds an­oth­er mar­quee name to its list of part­ners: GSK

Im­mat­ics, in its fe­cund deal spree, has lured GSK, as the British drug­mak­er re­fo­cus­es its at­ten­tion to the lu­cra­tive field of on­col­o­gy.

On Thurs­day, the pri­vate­ly-held im­muno-on­col­o­gy com­pa­ny se­cured $50 mil­lion up­front in a col­lab­o­ra­tion with GSK on two T cell re­cep­tor (TCR) ther­a­peu­tics fo­cused on sol­id tu­mors. If all goes well, Im­mat­ics stands to earn more than $550 mil­lion in mile­stone pay­ments, in ad­di­tion to tiered roy­al­ties for each prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER